The use of Aquaphor to prevent transepidermal water loss and to maintain electrolyte balance in preterm newborn infants in the first week of life.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN89579779

Enrollment

Registered

2004-09-30

Start date

2003-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Diseases: Transepidermal water loss (TEWL) Neonatal Diseases Transepidermal water loss (TEWL)

Interventions

Standard care compared with emollient (aquaphor) therapy in addition to standard care.

Eligibility

Inclusion criteria

Inclusion criteria: Not provided at time of registration

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
1. Fluid requirement in 1st week of life 2. Neonatal morbidity: electrolyte balance, metabolic balance, chronic lung disease, treated patent ductus arteriosus	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026